Myeloperoxidase is a major neutrophil protein which generates oxidants that are highly reactive, and if present in seminal fluid, could be potentially damaging to spermatozoa. We recruited young males aged 18-35 years, unscreened for fertility status, for a pilot study measuring seminal plasma myeloperoxidase. On three occasions, over a 3-month period, we measured parameters of semen quality and correlated these with seminal myeloperoxidase protein and activity. After baseline measurement, participants were supplemented daily with 250 mg of vitamin C, a potent scavenger of reactive oxygen species with antiinflammatory activities. Seminal plasma from eight of the 12 participants had measurable concentrations of myeloperoxidase protein, across a broad range (15-250 ng/mL). Median myeloperoxidase protein concentrations were~45-fold higher in semen samples with low vs. high sperm concentrations. Seminal plasma myeloperoxidase protein concentration was inversely correlated with the percentage of rapidly motile spermatozoa assessed by computer-assisted sperm analysis, and the total number of spermatozoa per ejaculate, but positively correlated with sperm maturity, measured by DNA staining ability. We measured an inverse correlation between semen vitamin C concentration and seminal plasma myeloperoxidase protein concentration, although vitamin C supplementation had no effect on semen quality. Our pilot data suggest that high concentrations of myeloperoxidase were present in the seminal plasma of many of our young participants, and that this may be associated with decreases in semen quality. A larger study is required to confirm these findings.
INTRODUCTION
The clinical significance of leucocytes in human ejaculate remains unclear despite much work being undertaken to decipher whether they play a role in male infertility (Aitken & Baker, 2013) . Neutrophils, account for 50-60% of seminal leucocytes, with macrophages (20-30%) and T lymphocytes (~5%) making up the remainder (Wolff, 1995) . While the origin of leucocytes in semen is not well understood, it is generally believed that macrophages and lymphocytes originate in the testicular interstitium and epididymis, and neutrophils in the lower reproductive tract particularly the seminal vesicles and the prostate (Wolff, 1995) . A semen leucocyte count greater than 1 9 10 6 leucocytes per mL is termed leukocytospermia (World Health Organization 2010) , and is thought to arise from infection of the secondary sexual glands, especially the prostate (Aitken & Baker, 2013) . Neutrophils and macrophages generate superoxide and hydrogen peroxide as part of their oxidative burst. Neutrophils contain large amounts of the haem enzyme myeloperoxidase that utilises the hydrogen peroxide generated, to produce hypochlorous acid and other highly reactive oxidants (Klebanoff et al., 2013) . These oxidants can damage cells and tissue and consequently have the potential to damage spermatozoa and alter sperm functions (Plante et al., 1994; Aitken et al., 1995; Henkel et al., 2005) . Therefore, the presence of leucocytes in semen could decrease the capacity for successful fertilisation. Neutrophil and macrophage oxidants may also damage sperm DNA with implications for both fertility and the ongoing health of the offspring (Lewis et al., 2013) .
There is evidence to suggest that leukocytospermia is associated with a decrease in semen quality (Wolff et al., 1990; Plante et al., 1994; Saleh et al., 2002; Aziz et al., 2004) , however, results are inconsistent (Tomlinson et al., 1993; Aitken et al., 1995; Kaleli et al., 2000; Ziyyat et al., 2008) . Many of these studies rely on a peroxidase stain to detect leucocytes which considerably underestimates leucocyte numbers in semen; this assay measures only intact neutrophils, while macrophages and lymphocytes are not detected (Villegas et al., 2002) . To accurately determine the function of leucocytes in the male reproductive tract, and their role in infertility, it is important to distinguish whether or not they have become activated (Aitken & Baker, 2013) . To this end, seminal plasma elastase has been used as a marker of neutrophil activation and degranulation in the male genital tract (Wolff & Anderson, 1988) . Several investigators have shown higher seminal plasma elastase levels in infertile men than in fertile men (Zopfgen et al., 2000; Zorn et al., 2000) , and correlations between elevated elastase concentrations and decreased semen quality (Wolff et al., 1990; Kopa et al., 2005) including DNA integrity (Zorn et al., 2000) . However, the effect on semen quality remains controversial, with some studies showing no relationship (Jochum et al., 1986; Maegawa et al., 2001; Eggert-Kruse et al., 2009; Tremellen & Tunc, 2010) , Like elastase, myeloperoxidase is also present in the azurophilic granules of neutrophils and is released upon activation. Neutrophils are the major source of myeloperoxidase in the body (Davies et al., 2008) , with much lower levels found in monocytes and possibly macrophages (Davies et al., 2008; van der Veen et al., 2009) , and it is an excellent biomarker of neutrophil activation (Stamp et al., 2012) . To the best of our knowledge, seminal plasma myeloperoxidase protein concentration has not been measured in human semen. The primary objective of our study was to determine the myeloperoxidase levels in human semen and correlate this with semen quality, including DNA damage, in a group of young men unscreened for fertility issues. Vitamin C is a potent scavenger of reactive oxygen species, including those generated by myeloperoxidase (Carr & Frei, 1999) , and it has other antiinflammatory activities (Block et al., 2009; May & Harrison, 2013; Ellulu et al., 2015; Jamalan et al., 2015) . We also investigated whether vitamin C supplementation, from tablets or a high vitamin C-containing food (kiwifruit), was able to influence myeloperoxidase levels and affect semen quality.
MATERIALS AND METHODS

Participants
This study was conducted according to the guidelines in the Declaration of Helsinki and all procedures involving human participants were approved by the New Zealand Health and Disability Ethics Committee (#13/STH/105/AM01). The study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12613000989741).
Males aged 18 to 35 years, of unknown fertility, were recruited from local universities and screened for eligibility. Exclusion criteria included: taking prescription medication (within past 3 months), excessive alcohol consumption (>21 standard drinks/week), high fruit and vegetable consumption (>5 servings per day), allergy/intolerance to kiwifruit, taking vitamin C-containing supplements (within past 3 months), recent smoker (within previous year), diabetes mellitus, bleeding disorders and fainting because of fear of needles. Anthropometric measures were performed and a fasting venous blood sample was taken to determine plasma vitamin C status. In order to ensure that the vitamin C intervention was able to affect semen vitamin C levels, only participants with plasma vitamin C levels <50 lmol/L at baseline were recruited.
Using data from our previous studies (Carr et al., 2013 and A. Carr, unpublished observations) , sample size calculations indicated that, at 80% power and a significance level of 0.05, a sample size of 12 participants would be required to detect a difference of 100 lmol/L in seminal vitamin C concentration. Therefore, 14 non-smoking participants were enrolled (with allowance for 20% withdrawal). All participants provided written informed consent.
Study design
Our study design is shown in Fig. 1 . Semen was obtained at baseline, then following the first intervention phase of 4 weeks (during which participants consumed two Zespri SunGold kiwifruit per day equivalent to 250 mg/day vitamin C) and after the second intervention phase which consisted of 10 weeks, supplementation with 250 mg/day vitamin C tablets. This second period was to allow the participants' vitamin C levels to remain at saturating concentrations for an entire cycle of spermatogenesis (about 3 months). Fasting blood samples were also collected to monitor plasma vitamin C levels.
Two participants were excluded from data analysis; one missed baseline measurements and was subsequently withdrawn, and another withdrew prior to post-intervention measurements; thus, 12 participants completed the first phase of the intervention. Eight participants completed the second phase of the intervention as four of the 12 participants were excluded; one was lost to follow-up, one declined to participate and two withdrew prior to the vitamin C tablet intervention.
Intervention
Gold kiwifruit (Actinidia chinensis var Sungold) were provided by Zespri International Ltd. (Mount Manganui, New Zealand) and were stored at ≤4°C. The vitamin C content of the fruit was measured by HPLC with electrochemical detection (Carr et al., 2012) . Participants consumed two kiwifruit per day over the 4-week vitamin C intervention period; analysis indicated that the vitamin C content of two peeled kiwifruit was~259 mg. 432 Andrology, 2017, 5, 431-438
Chewable orange-flavoured vitamin C tablets were provided by Tishcon Corp., Westbury, NY, USA. Analysis of the tablets indicated that they contained 49 mg of vitamin C per tablet. For the second intervention period, participants consumed five tablets per day (~245 mg/day vitamin C) over the 10 weeks.
Sample collection
Plasma
Venous blood was collected into 4 mL K 3 -EDTA vacutainer tubes (Becton Dickinson; Auckland, New Zealand) and immediately placed on ice. Samples were centrifuged at 4°C and the plasma removed for vitamin C analysis.
Semen donation
Semen samples were collected by masturbation after 2-4 days of sexual abstinence. Participants were provided with specimen collection guidelines and pre-weighed specimen containers.
Semen quality analysis
Semen quality analysis was performed immediately following sample liquefaction for at least 20 min at room temperature (World Health Organization 2010). Total ejaculate volume was determined by semen weight, sperm concentration and total spermatozoa per ejaculate were calculated using a haemocytometer and sperm vitality was estimated by assessing membrane integrity using eosin Y staining (World Health Organization 2010). Routine quality control assessments were not undertaken.
Computer-assisted sperm analysis
Sperm motility was evaluated using computer-assisted sperm analysis (CASA; Hamilton-Thorne Research, Beverly MA, USA). CASA is considered adequate for routine diagnostic application (World Health Organization 2010). After 20 min liquefaction, and within 60 min of sample production, an aliquot of semen was loaded on to a pre-warmed 37°C chamber slide with a depth of 20 lm (Leja slide, Spectrum Technologies, Healdsburg, CA, USA) and then placed on a heated microscope stage (37°C). Sperm motility was recorded using a video camera (XC-ST50 Sony, Tokyo, Japan) mounted on an external phase contrast microscope (CX41, Olympus, Melville, NY, USA) with a 109 negative phase objective (Mitra et al., 2010) . Two replicates (i.e. two different slide chambers for each male) we used for each male and the average value was used for analyses; 4-7 different fields of view, corresponding to an average of 1019 sperm cells, were analysed (95% confidence limits AE 361.01, n = 54 semen samples). There was high within-sample repeatability. The parameters set for the CASA were as follows: frame rate (Hz) 60, number of frames acquired 60, minimum contrast 80, minimum size (pixels) 3, cell size (pixels) 6, VAP (lm/s) 25, STR (%) 80, slow cells static, VAP cut-off (lm/s) 10, VSL cutoff (lm/s) 10. Rapid progressive motility is defined as VAP >25 and STR >80. We measured average path velocity (VAP, lm/sec), average curvilinear velocity (VCL, lm/sec), straight line velocity (VSL, lm/sec), linearity (LIN, %: the average ratio of VSL/VCL, percentage), straightness (STR %: the average value of the ratio VSL/VAP).
Sperm morphology
Five to 10 lL of semen was smeared on a microscope slide, air-dried overnight and fixed by immersion in 95% ethanol. Slides were then stained with Papanicolaou stain (World Health Organization 2010). Morphology was assessed at Canterbury Southern Community Laboratories (Christchurch, New Zealand) and presented as percentage of normal forms.
Sperm chromatin structure assay
The sperm DNA fragmentation index (DFI %) and high DNA stainability (HDS %) were measured by the sperm chromatin structure assay (SCSA) (Evenson, 2013) . Semen samples (300 lL) were flash frozen in liquid nitrogen immediately following liquefaction. SCSA was carried out at the Malaghan Institute (Wellington, New Zealand).
Analysis of myeloperoxidase
The myeloperoxidase protein concentration and activity in semen were analysed simultaneously using a sandwich ELISA (Stamp et al., 2012) . In this assay, myeloperoxidase is initially captured with a monoclonal anti-myeloperoxidase antibody (Abcam, Cambridge, UK) and its activity is measured using hydrogen peroxide and Amplex Red. The plate is then washed and the amount of myeloperoxidase bound to the plate is determined using a rabbit polyclonal myeloperoxidase antibody (produced in house, UOC). A standard curve was prepared from purified myeloperoxidase, which is assumed to be 100% active, and the protein and activity levels in samples were calculated (expressed as ng/mL). The specific activity of myeloperoxidase was calculated from the ratio of myeloperoxidase activity vs. myeloperoxidase protein, excluding any samples with <10 ng/ mL myeloperoxidase protein to prevent overestimation, and is expressed as a percentage.
Vitamin C analysis
Plasma or liquefied semen samples were mixed with an equal volume of ice-cold perchloric acid (0.54 mol/L), containing the metal chelator DTPA (100 lmol/L), on ice, then pelleted to remove protein. Supernatants were stored at À80°C prior to analysis by HPLC with electrochemical detection as described previously (Carr et al., 2012) . A standard curve of ascorbic acid was run daily and the calculated semen and plasma vitamin C content is expressed as lmol/L.
Statistical analysis
Data are presented as mean AE SEM, unless stated otherwise, and analysis of paired data was carried out using two-tailed Student's t-test with significance determined as p < 0.05 (Sigma Plot v13.0, Systat Software Inc., San Jose, CA, USA). The t-tests for unequal variance were performed in www.openepi.com. Correlations were tested using Kendall Tau rank correlation using SPSS software (version 22, IBM Corp., Armonk, NY, USA).
RESULTS
Participant characteristics
Thirty-five healthy young men were screened for the study and 14 individuals with below-average plasma vitamin C status (<50 lmol/L) were recruited. Twelve individuals completed phase 1, and eight of the recruited cohort completed the phase 2 of the study. The baseline characteristics and semen quality measures of individuals who completed the two phases of the study are shown in Table 1 . There was no statistically significant difference between the two groups.
Seminal plasma myeloperoxidase
Analysis of seminal plasma myeloperoxidase protein levels showed a wide range of detectable protein levels, with eight of the 12 individuals having elevated myeloperoxidase protein concentrations (15-250 ng/mL) in at least one of their samples and others having no myeloperoxidase protein in their seminal plasma (Table 2 ). In contrast to the measured protein levels, myeloperoxidase activity was not detectable in the majority of participants' seminal plasma (Table 2) .
To further investigate the observed difference between myeloperoxidase protein and activity levels in seminal fluid, samples obtained after the second phase of intervention were separated into fractions (whole semen, cell pellet and seminal plasma). Myeloperoxidase protein was measurable in all three fractions, and was evenly distributed between the cells and seminal plasma (Fig. 2 ). This contrasted with enzyme activity, which was much lower in the seminal plasma than in the cellular fraction (Fig. 2) , suggesting inhibition of the enzyme in the extracellular compartment. Calculation of the specific activity of the fractions, using those samples with at least 10 ng/mL myeloperoxidase protein to prevent overestimation of specific activity, also showed that myeloperoxidase was significantly inactivated in the seminal plasma, with only~13% being active (Fig. 2) . This was significantly different to the cell pellet fraction in which myeloperoxidase was completely active, with the specific activity of myeloperoxidase measured at~114% (p = 0.006).
Seminal plasma myeloperoxidase and sperm concentration
Extracellular myeloperoxidase reflects the protein released from activated neutrophils and we have therefore investigated the relationship between semen quality and myeloperoxidase protein concentration in the seminal plasma, as a marker of active inflammation. We observed a strong inverse correlation between the myeloperoxidase protein concentration and sperm concentration ( Fig. 3 and Table 3 ). Myeloperoxidase protein concentrations were~45-fold higher in samples with below median sperm concentration, compared to those in the above median sperm concentration group ( Fig. 3 ; p < 0.001). The total sperm count per ejaculate was also inversely correlated with Data represent mean AE SD; n = 11-12 for phase 1 and n = 7-8 for phase 2 of the intervention. Sperm velocity parameters were positively correlated (VAP-VSL, r = 0.80, p < 0.0001, n = 54; VCL-VSL r = 0.47, p < 0.001, n = 54); therefore, we report VAP as our measure of sperm velocity. All average semen parameters tested ( a ) are well above the WHO reference ranges for fertile men (World Health Organization 2010), with sperm rapid progressive motility ( b ) above the reference value from the fourth edition WHO manual (World Health Organization 1999). Figure 2 Comparison of myeloperoxidase protein concentration, activity and specific activity in whole semen, cell fraction and seminal plasma from phase 2 intervention samples. Myeloperoxidase activity and protein are shown as ng/mL after estimation from standard curves of purified plantar myeloperoxidase with assumed 100% activity relative to a known protein standard. Specific activity was calculated from the ratio of myeloperoxidase activity to protein concentration and is expressed as a percentage. White bars represent the cell pellet, black bars the seminal plasma and mid-grey bars the whole semen (mean AE SEM). Statistical differences were tested using two-sample independent t-tests with n = 3-5; three samples were excluded because of undetectable myeloperoxidase protein and activity in all three fractions, and a further two samples were removed from the calculation of specific activity as MPO protein was <10 ng/mL.
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High seminal plasma myeloperoxidase protein levels were inversely correlated with a decreased percentage of rapidly motile spermatozoa as determined by CASA (Table 3 ). The % motile also showed an inverse correlation with a trend towards significance (Table 3) . There was no association with other kinematic measures of sperm velocity (Table 3 ). The percentage of cells with high DNA staining (HDS %) showed a significant positive correlation with seminal plasma myeloperoxidase concentration (Table 3 ). We also found that seminal fluid myeloperoxidase protein was inversely correlated with semen vitamin C levels (Table 3) .
Vitamin C supplementation
Plasma vitamin C measurement indicated that participants reached saturation concentrations (>70 lmol/L) within one week of supplementation with two kiwifruit/day, and remained at this level for the duration of the intervention phases (data not shown). There was a statistically significant increase in semen vitamin C levels, from 378 AE 63 lmol/L (mean AE SEM) at baseline to 529 AE 99 lmol/L after the kiwifruit phase (p = 0.022), with a further non-significant increase to 659 AE 248 lmol/L after the tablet phase (p = 0.194). The increased semen vitamin C levels were not associated with a change in any of the measures of semen quality, including DNA fragmentation, or changes in myeloperoxidase protein concentrations or activity (data not shown).
DISCUSSION
Our understanding of the role played by leucocytes in male infertility is poor, with many questions remaining unanswered. For this reason exploring leucocyte subtypes in semen, their activation status, production of 'biomarkers' and their relationship with semen quality in specific groups may provide some insight (Tremellen & Tunc, 2010; Fathy et al., 2014; Urbschat et al., 2015) . In this study, we have shown that the neutrophil enzyme myeloperoxidase is present in the seminal plasma, of apparently healthy young men, in both the cellular and extracellular compartments, and have found that extracellular levels were associated with poor sperm numbers and motility. This is a pilot study with a small cohort, but we have observed a highly significant correlation between neutrophil myeloperoxidase levels in seminal plasma and markers of male fertility that has not previously been reported.
Myeloperoxidase is often used as a biomarker for the presence of leucocytes, but few have considered the relevance of its activation state. We have been able to measure myeloperoxidase specific activity, as our assay measures both the protein concentration and activity (Stamp et al., 2012) and we have shown that the enzyme is largely inactivated in the extracellular compartment. This contrasts with the intracellular enzyme which retains activity. The extracellular myeloperoxidase-derived fraction is likely to have been released from activated neutrophils and can be inhibited by the hypochlorous acid generated through its reaction with hydrogen peroxide (Maitra et al., 2013; PaumannPage et al., 2013) . Therefore, inactive myeloperoxidase may be indicative of leucocyte-derived oxidant generation, although it is also possible that the enzyme may have been inactivated by binding of seminal plasma proteins, such as ceruloplasmin (Orlando et al., 1985; Segelmark et al., 1997; Chapman et al., 2013) . Further investigation will be required to characterise the underlying mechanism of inactivation.
We observed a strong correlation between myeloperoxidase protein concentration in seminal plasma, and low sperm concentration, over the course of the study. The association with myeloperoxidase was more marked than the observed observation with neutrophil elastase, which has been variable (Jochum et al., 1986; Maegawa et al., 2001; Eggert-Kruse et al., 2009; Tremellen & Tunc, 2010) . Tremellen and co-workers showed no relationship between neutrophil elastase concentration and any marker of semen quality in a group of 63 infertile men. In contrast, neopterin, a marker of macrophage activation, was Figure 3 Correlation of seminal plasma myeloperoxidase (MPO) protein concentration and sperm concentration. Samples were divided around the median sperm count of 56.5 9 10 6 /mL of seminal plasma (below/equal median group n = 17; above median group n = 16). Box plots show medians with 25th and 75th percentiles as boundaries, whiskers are the 10th and 90th percentiles and symbols indicate outliers. The seminal plasma myeloperoxidase protein concentration was significantly different between the two groups (two-sample independent t-test with unequal variances). significantly correlated with decreased semen quality (including sperm concentration, morphology, DNA fragmentation and oxidative stress markers). The reason for the difference between our myeloperoxidase results and the majority of the elastase studies is unclear. However, it is possible that myeloperoxidase is a more reliable biomarker for neutrophil activation, as extracellular elastase is specifically targeted by a number of protease inhibitors and its turnover may be affected as a result. It may be that myeloperoxidase, as an excellent biomarker for oxidative stress, may be more closely correlated with sperm damage. While our results demonstrate an association between seminal plasma myeloperoxidase protein concentration and sperm count, they provide no information on the direction of the relationship. It is possible that, rather than causing the decrease in sperm concentration, myeloperoxidase may be present as a consequence of spermatozoa being of low quality and becoming apoptotic or damaged within the male reproductive tract, thereby attracting neutrophils, to remove defective cells (Aitken & Baker, 2013; Hochreiter-Hufford & Ravichandran, 2013) . The site at which neutrophil infiltration of the male reproductive tract occurs is uncertain. Phagocytes are rarely seen in the epididymal lumen (Wolff, 1995) , and therefore, if neutrophils were involved in the removal of defective spermatozoa, this would need to occur in more distal portions of the tract. This would preclude the prostate and seminal vesicles, where the presence of neutrophils is well established, as neutrophils from these glands should only come into contact with spermatozoa at the point of ejaculation (Aitken & Baker, 2013) . A recent study has shown the presence of myeloperoxidase in the glandular epithelial cells of the prostate (Roumeguere et al., 2012) ; however, the importance of this is unclear. How and where inflammatory processes are able to impact on sperm health should be a focus for future studies.
We found that seminal plasma myeloperoxidase protein concentration correlated with some markers of sperm motility, particularly the percentage of rapidly motile spermatozoa (r = À0.327, p = 0.021), suggesting that oxidative stress affects this function. Rapidly motile spermatozoa are those most likely to efficiently penetrate cervical mucus and are therefore indicative of the ability to fertilise (Bjorndahl, 2010) . We also observed a positive correlation between seminal plasma myeloperoxidase protein concentration and high DNA staining as measured by the SCSA assay. High DNA staining is thought to represent immature spermatozoa in which the chromatin is not fully condensed, allowing greater access of the fluorescent label to the DNA (Evenson, 2013) . Thus, it supports the premise that neutrophils may be involved in clearing immature spermatozoa from the reproductive tract.
Myeloperoxidase protein concentrations in seminal plasma were up to 10-20-fold higher than those previously measured in the blood plasma of healthy controls (Stamp et al., 2012 (Stamp et al., , 2014 . Indeed, concentrations in many of the semen samples were comparable to, or even higher than, those measured in the blood plasma of patients with an acute inflammatory disease such as gout (Stamp et al., 2014) . These results suggest a significant level of inflammation in our cohort, which is a surprising finding given that the young men in this study were not recruited based on their fertility status, and would be expected to represent a 'healthy' cohort. It may be of interest to note that one participant (#8) had raised seminal plasma myeloperoxidase concentrations in his first two samples, but no detectable myeloperoxidase protein in his seminal fluid after the second intervention phase; this individual was taking antiinflammatory medication for several days prior to providing this sample. A larger study would be necessary to determine the relationship between myeloperoxidase in seminal plasma and active inflammation.
We also tested whether seminal fluid vitamin C levels were able to affect semen quality. As a known antioxidant, vitamin C could potentially offset oxidative injury to spermatozoa. Seminal fluid vitamin C levels are also significantly higher than plasma levels and are well conserved, indicating a necessary (but unknown) function (Carr et al., 2013) . Following supplementation with either kiwifruit or a tablet intervention, seminal fluid vitamin C levels were significantly raised, but we saw no changes in semen quality. This may be because of the small numbers of individuals who actually completed the study. Nevertheless, we did observe an inverse association between seminal plasma myeloperoxidase protein concentration and semen vitamin C concentration, suggesting a potential antiinflammatory activity. This possibly reflects the consumption of vitamin C by myeloperoxidase-derived oxidants (Carr et al., 2001) .
In conclusion, the findings of our pilot study suggest a relationship between high concentrations of myeloperoxidase protein concentration in seminal plasma and low sperm concentration in a group of young males not recruited on the basis of their fertility status. A larger study is required to confirm and expand on the observed correlations. Surprisingly, many of our young participants had an elevated myeloperoxidase protein concentration in their seminal plasma, much of which had been inactivated, possibly reflecting excessive neutrophil activation. The presence of such excessive amounts of this protein within the reproductive tract of a young, and otherwise healthy male population, demands further investigation.
